Bioconjugation is a cornerstone of antibody-drug conjugate (ADC) development, enabling precise linking of biologically active molecules to potent payloads. Abzena’s bioconjugation expertise supports the creation of stable and effective ADCs, combining innovation with reliability across every stage of development.
Through proprietary platforms such as ThioBridge™, Abzena provides site-specific conjugation that ensures superior drug-antibody ratio (DAR) control and improved ADC stability. Complemented by a comprehensive conjugation toolbox, the company offers tailored solutions spanning early discovery to cGMP manufacturing, with extensive experience in handling a diverse range of payloads and linker designs.
From advanced analytics and stability profiling to optimized release kinetics, Abzena’s integrated approach accelerates the path from discovery to clinic, helping biopharma partners achieve efficient, high-quality ADC development.
Download the white paper here to learn how Abzena’s tailored bioconjugation services can streamline your ADC programme and drive clinical success.
